Trial Profile
A phase I study of capecitabine, cisplatin and imatinib in patients with unresectable or metastatic gastric cancer.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 20 Oct 2022
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary) ; Cisplatin (Primary) ; Imatinib (Primary)
- Indications Gastric cancer
- Focus Adverse reactions; Therapeutic Use
- 20 Jul 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 20 Jul 2011 Actual end date (Jan 2011 ) added as reported by ClinicalTrials.gov.
- 18 Feb 2008 New trial record.